pcn poster

Posters

Alternating Hemi-auto-prosopometamorphopsia (Cerebral Asthenopia) of Kith and Kin Mirror Hallucinations.

Prosopometamorphopsia has been noted to be one of the rare symptoms of schizophrenia. Our patient, with schizoaffective disorder, presented with hemi-autoprosopometamorphopsia with half o...

Shreya Dutt , MBBS;

10/26/2023

An Updated Meta-Analysis of the Clinical Utility of Combinatorial Pharmacogenomic Testing for Adult Patients with Depression

This updated meta-analysis investigating the clinical utility of combinatorial pharmacogenomic testing in adult patients (Nf3,532) with depression found that care guided by access to the ...

Melissa P. Dyer , PhD;

10/26/2023

Application of AASM Clinical Significance Thresholds to Once-Nightly Sodium Oxybate for Improvement in Narcolepsy Symptoms

Results from the phase 3 REST-ON trial that demonstrated efficacy/safety of extended-release sodium oxybate (once-nightly sodium oxybate [ON-SXB]; LUMRYZ™) were published after the cutoff...

Thomas Roth , PhD;

10/26/2023

Are Same Day Clozapine Levels Necessary?

The learning objective is to illustrate clinical scenarios where same-day clozapine blood levels are critical to patient care. Though therapeutic drug monitoring is standard-of-care beca...

Megan J. Ehret , PharmD, MS, BCPP;

10/26/2023

Aripiprazole 2-Month Ready-to-Use: A Novel Long-Acting Injectable Antipsychotic Formulation for Administration Once Every 2 Months

Aripiprazole 2-month ready-to-use (Ari 2MRTU) is a novel long-acting injectable formulation of aripiprazole monohydrate for gluteal intramuscular administration. In the US, Ari 2MRTU is a...

Murat Yildirim , MD, PhD;

10/26/2023

Aripiprazole Lauroxil 2-Month Formulation for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Study

Positive and Negative Syndrome Scale (PANSS) factor scores (as described by Marder) were assessed in a post hoc analysis of data from adults with acute schizophrenia who received 25-week ...

Leslie Citrome , MD;

10/26/2023

Aripiprazole Once-Monthly for the Treatment of Adult Patients in the Earlier Stages of Bipolar I Disorder – a Post Hoc Analysis of Data From a Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Trial

This post hoc analysis of data from a double-blind, placebo-controlled, 52-week randomized-withdrawal trial (NCT01567527) was conducted to evaluate the efficacy of aripiprazole once-month...

Karimah S. Bell Lynum , PharmD, MBA, BCPP;

10/26/2023

Adjunctive Brexpiprazole in Patients With Major Depressive Disorder Including in a Subgroup With Energy/Concentration Symptoms: Time to Efficacy Onset

This post hoc pooled analysis of three randomized, fixed-dose, 6-week studies explored time to efficacy onset of adjunctive brexpiprazole 2–3 mg/day in patients with major depressive diso...

Shivani Kapadia ;

10/26/2023

Assessment of Withdrawal Symptoms after Discontinuation of AXS-05 (Dextromethorphan-Bupropion) Treatment: Results from the GEMINI Trial

The GEMINI trial evaluated withdrawal symptoms in MDD patients after a 6-week treatment with AXS-05. Upon discontinuation, symptoms were assessed using the PWC-20. Results showed no signi...

Matthew J. Baker , PharmD;

10/26/2023

"When Perception Deceives: Unmasking Bilateral Occipito-Parietal Infarcts Presenting as Complex Hallucinations and Self-Harm"

Case of a 51-year-old veteran with no prior psychiatric history who presented to the ED with self-inflicted injury and positive symptoms (both CAH, VH), and was transferred to inpatient p...

Jaberpreet Dhaliwal , DO;

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products